MUNICH — Eplontersen, a drug already approved for polyneuropathy caused by transthyretin (TTR) amyloid deposits, does not protect against cardiovascular events or death associated with TTR-mediated amyloid cardiomyopathy (ATTR-CM), according to a phase 3 trial. With up to 140 weeks of follow-up, the rate of the primary endpoint of cardiovascular mortality or events was 11% …
Read More
Phase 3 Eplontersen Trial Results Disappoint
